Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS107 vs investigator's choice in CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma (≥2L)
CTR20254590Phase 3Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of JS107 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Progression-free survival by blinded independent central review (BICR-PFS) and Overall survival. Started Jan 2026; status: active.
02
Drugs
JS107
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20254590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254590.